The ALK/MET/ROS1 inhibitor crizotinib [20] is approved for the treatment of non-small cell lung carcinoma (NSCLC) with ALK translocations [21–23] and is also being tested in neuroblastoma (clinical trial: NCT00939770) [24]. This evidence concerns the gene ROS1 and neuroblastoma.